ClinicalTrials.gg
CompletedNCT02362035KEYNOTE145Updated May 13, 2026Results posted

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

A Phase 1/2 interventional study of Acalabrutinib and Pembrolizumab in Follicular Lymphoma (FL), CLL and Small Lymphocytic Lymphoma (SLL), sponsored by Acerta Pharma BV. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
161
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Lymphoma, Follicular by AstraZeneca — 4 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Follicular · AstraZeneca.

Enrollment
7th of 16
161 · median 130
Started
2015
the only one that year
Phase 1/2
4 of 17
1 open now
Registered
7th of 17
by date

Among the 17 studies in Lymphoma, Follicular by AstraZeneca, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2015, is one of 4 in phase 1/2, and was the 7th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

4 of the 17 studies in Lymphoma, Follicular by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma, Follicular by AstraZeneca, or all of them as a file.
02

Study summary

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

Read the detailed description

This is a Phase 1b/2, open-label, nonrandomized study that will be conducted in 2 stages. In the first stage, Part 1 of the study will determine the safety and preliminary efficacy of acalabrutinib and pembrolizumab in a limited group of B-cell malignancies. In the second stage, Part 2 allows for possible expansion cohorts into a wider range of B-cell malignancies, and Part 3 will evaluate the combination in subjects with myelofibrosis (MF).

03

Conditions studied

  • Follicular Lymphoma (FL)
  • CLL
  • Small Lymphocytic Lymphoma (SLL)
  • Richter's Syndrome
  • Mantle Cell Lymphoma (MCL)
  • Indolent Non Hodgkin Lymphoma
  • Waldenström Macroglobulinemia
  • Multiple Myeloma
  • Hodgkin Lymphoma
  • Burkitt Lymphoma
  • Marginal Zone Lymphomas
  • Mediastinal Large B Cell Lymphoma
  • Hairy Cell Leukemia

Keywords

  • Bruton tyrosine kinase inhibitor
  • Btk
  • B-Cell Malignancies
  • Mantle Cell
  • Multiple Myeloma
  • CLL
  • SLL
  • DLBCL
  • Follicular
  • Waldenstrom
  • Burkitt lymphoma
  • marginal zone lymphomas
  • hairy cell leukemia
  • B cell acute lymphoid leukemia
  • Acalabrutinib
  • ACP-196
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Diagnosis of a hematologic as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
  • (ECOG) performance status of ≤ 1.
  • Agreement to use during the study and for 90 days after the last dose of ACP-196 or 120 days after the last dose of pembrolizumab, if sexually active and able to bear or beget children.
  • Completion of all therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or therapy) for the treatment of cancer ≥ 4 weeks before the start of study therapy.
  • ≥ 0.5 x 10\^9/L or count ≥ 50 x 10\^9/L unless due to disease involvement in the bone marrow.

Main Exclusion Criteria:

  • A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of study drugs, or put the study outcomes at undue risk.
  • Central nervous system (CNS) involvement by lymphoma/leukemia
  • Any therapeutic antibody within 4 weeks of first dose of study drugs.
  • Total > 1.5 x ; and (AST) or alanine aminotransferase (ALT) > 3.0 x ULN.
  • Estimated of \< 30 mL/min, calculated using the formula of Cockcroft and Gault (140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Acalabrutinib plus Pembrolizumab

    A nonrandomized study that will be conducted in 2 stages. In the first stage, (Safety), subjects will receive Acalabrutinib Dose A orally administered (PO) twice daily (BID) in combination with Pembrolizumab Dose B administered every 3 weeks (Q3W). The second stage was an expansion of Cohorts with the same dose regimen as the first stage. An additional expansion in subjects with Myelofibrosis was planned but not conducted.

    Drug: Acalabrutinib · Drug: Pembrolizumab

Interventions

  • Orally Administered (PO)

    Also known as: ACP-196

  • Intravenous Administered (IV)

    Also known as: KEYTRUDA

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)

    Treatment-emergent AEs were defined as those events that occurred on or after the first dose of study drug, through the treatment phase, and within 30 days following the last dose of study drug.

    Time frame: 104 weeks

  2. Number of Participants With Grade 3-4 Adverse Events

    Severity of AEs was graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03

    Time frame: 104 weeks

  3. Number of Participants With Grade 5 Adverse Events

    Number of participants with CTCAE Grade 5 (fatal) adverse events

    Time frame: 104 weeks

  4. Number of Participants With Any Study-Drug Related AE

    Study drug-related AEs were those assessed by investigator as related to study treatment.

    Time frame: 104 weeks

  5. Number of Participants With Grade 3-4 Study-Drug Related AE

    The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.

    Time frame: 104 weeks

  6. Number of Participants With Grade 5 Study-Drug Related AE

    Grade 5 (fatal) AEs assessed by investigator as related to study treatment.

    Time frame: 104 weeks

  7. Number of Participants With Any SAE

    Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.

    Time frame: 104 weeks

  8. Number of Participants With Grade 3-4 Any SAE

    Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher.

    Time frame: 104 weeks

  9. Number of Participants With Grade 5 Any SAE

    Grade 5 events were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.

    Time frame: 104 weeks

  10. Number of Participants With Any Study Drug-Related SAE

    Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.

    Time frame: 104 weeks

  11. Number of Participants With Any Grade 3-4 Study Drug-Related SAE

    Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.

    Time frame: 104 weeks

  12. Number of Participants With Any Grade 5 Study Drug-Related SAE

    Grade 5 AEs were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.

    Time frame: 104 weeks

  13. Number of Participants With AE Leading to Study Drug Discontinuation, Modification or Delay

    AEs that discontinuation of study treatment, or a reduction in dosage, or a delay (temporary withholding) in treatment.

    Time frame: 104 weeks

  14. Number of Participants With AE Leading to Study Drug Discontinuation

    An adverse event that resulted in the permanent discontinuation of study treatment in the study.

    Time frame: 104 weeks

  15. Number of Participants With AE Leading to Study Drug Delay

    An adverse event that caused a temporary withholding of study treatment.

    Time frame: 104 weeks

  16. Number of Participants With AE Leading to Study Drug Modification

    An adverse event that resulted in a reduction in the dosage of study treatment for that participant.

    Time frame: 104 weeks

Secondary outcomes

  1. Overall Response Rate

    The percentage of subjects who achieve a partial response or complete response

    Time frame: 104 weeks

  2. Duration of Response

    The interval from the first documentation of response to the earlier of the first documentation of definitive disease progression or death from any cause

    Time frame: 104 weeks

  3. Progression-free Survival

    The interval from the first dose date of acalabrutinib or pembrolizumab to the earlier of the first documentation of objective disease progression or death from any cause

    Time frame: 104 weeks

  4. Overall Survival

    The time from the first dose date of acalabrutinib or pembrolizumab until date of death due to any cause

    Time frame: 104 weeks

  5. Time to Next Treatment

    The time from the first dose date of acalabrutinib or pembrolizumab to the start of the next treatment other than the study treatment

    Time frame: 104 weeks

07

Results

Posted May 6, 2022

Participant flow

Participant flow — Overall Study
MilestoneAcalabrutinib + Pembrolizumab
Started161
Completed0
Not completed161
Withdrew: Death67
Withdrew: Lost to follow-up3
Withdrew: Adverse event1
Withdrew: Physician decision1
Withdrew: Subject started another cancer therapy10
Withdrew: Study terminated by sponsor45
Withdrew: Decision by subject not related to ae/sae2
Withdrew: Decision by pi not related to ae/sae1
Withdrew: Disease progression11
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

Treatment-emergent AEs were defined as those events that occurred on or after the first dose of study drug, through the treatment phase, and within 30 days following the last dose of study drug.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Treatment Emergent Adverse Events (AEs)160
PrimaryNumber of Participants With Grade 3-4 Adverse Events

Severity of AEs was graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Grade 3-4 Adverse Events
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Grade 3-4 Adverse Events105
PrimaryNumber of Participants With Grade 5 Adverse Events

Number of participants with CTCAE Grade 5 (fatal) adverse events

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Grade 5 Adverse Events
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Grade 5 Adverse Events9
PrimaryNumber of Participants With Any Study-Drug Related AE

Study drug-related AEs were those assessed by investigator as related to study treatment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Any Study-Drug Related AE
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Any Study-Drug Related AE142
PrimaryNumber of Participants With Grade 3-4 Study-Drug Related AE

The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Grade 3-4 Study-Drug Related AE
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Grade 3-4 Study-Drug Related AE66
PrimaryNumber of Participants With Grade 5 Study-Drug Related AE

Grade 5 (fatal) AEs assessed by investigator as related to study treatment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Grade 5 Study-Drug Related AE
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Grade 5 Study-Drug Related AE3
PrimaryNumber of Participants With Any SAE

Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Any SAE
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Any SAE75
PrimaryNumber of Participants With Grade 3-4 Any SAE

Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Grade 3-4 Any SAE
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Grade 3-4 Any SAE64
PrimaryNumber of Participants With Grade 5 Any SAE

Grade 5 events were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Grade 5 Any SAE
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Grade 5 Any SAE9
PrimaryNumber of Participants With Any Study Drug-Related SAE

Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Any Study Drug-Related SAE
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Any Study Drug-Related SAE34
PrimaryNumber of Participants With Any Grade 3-4 Study Drug-Related SAE

Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. The severity of the AEs was assessed by NCI CTCAE Version 4.03 or higher. Drug-related AEs were those assessed by investigator as related to study treatment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Any Grade 3-4 Study Drug-Related SAE
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Any Grade 3-4 Study Drug-Related SAE30
PrimaryNumber of Participants With Any Grade 5 Study Drug-Related SAE

Grade 5 AEs were fatal events. Serious AEs were those that resulted in death, were life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product, or were considered a significant medical event by the investigator based on medical judgment. Drug-related AEs were those assessed by investigator as related to study treatment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With Any Grade 5 Study Drug-Related SAE
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With Any Grade 5 Study Drug-Related SAE3
PrimaryNumber of Participants With AE Leading to Study Drug Discontinuation, Modification or Delay

AEs that discontinuation of study treatment, or a reduction in dosage, or a delay (temporary withholding) in treatment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With AE Leading to Study Drug Discontinuation, Modification or Delay
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With AE Leading to Study Drug Discontinuation, Modification or Delay83
PrimaryNumber of Participants With AE Leading to Study Drug Discontinuation

An adverse event that resulted in the permanent discontinuation of study treatment in the study.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With AE Leading to Study Drug Discontinuation
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With AE Leading to Study Drug Discontinuation45
PrimaryNumber of Participants With AE Leading to Study Drug Delay

An adverse event that caused a temporary withholding of study treatment.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With AE Leading to Study Drug Delay
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With AE Leading to Study Drug Delay71
PrimaryNumber of Participants With AE Leading to Study Drug Modification

An adverse event that resulted in a reduction in the dosage of study treatment for that participant.

Time frame:
104 weeks
Reported as:
Number · Number of participants
Number of Participants With AE Leading to Study Drug Modification
Number of participantsAcalabrutinib + Pembrolizumab
Number of Participants With AE Leading to Study Drug Modification9
SecondaryOverall Response Rate

The percentage of subjects who achieve a partial response or complete response

Time frame:
104 weeks
Reported as:
Number · percent
Overall Response Rate
percentAcalabrutinib + Pembrolizumab
Overall Response Rate38.5 (31.0 to 46.5)
SecondaryDuration of Response

The interval from the first documentation of response to the earlier of the first documentation of definitive disease progression or death from any cause

Time frame:
104 weeks
Reported as:
Median · Months
Duration of Response
MonthsAcalabrutinib + Pembrolizumab
Duration of Response28.5 (9.0 to 36.4)
SecondaryProgression-free Survival

The interval from the first dose date of acalabrutinib or pembrolizumab to the earlier of the first documentation of objective disease progression or death from any cause

Time frame:
104 weeks
Reported as:
Median · Months
Progression-free Survival
MonthsAcalabrutinib + Pembrolizumab
Progression-free Survival4.7 (3.3 to 6.9)
SecondaryOverall Survival

The time from the first dose date of acalabrutinib or pembrolizumab until date of death due to any cause

Time frame:
104 weeks
Reported as:
Median · Months
Overall Survival
MonthsAcalabrutinib + Pembrolizumab
Overall Survival50.4 (26.2 to NA)
SecondaryTime to Next Treatment

The time from the first dose date of acalabrutinib or pembrolizumab to the start of the next treatment other than the study treatment

Time frame:
104 weeks
Reported as:
Median · Months
Time to Next Treatment
MonthsAcalabrutinib + Pembrolizumab
Time to Next Treatment21.1 (10.5 to 34.7)

Adverse events

Collected over For each subject, adverse event data were collected from first dose of study drug until 30 days after the last dose, until the end of the study (data cutoff date of 14 July 2020).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acalabrutinib + Pembrolizumab69/161 (42.9%)75/161 (46.6%)157/161 (97.5%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventAcalabrutinib + Pembrolizumab
PneumoniaInfections and infestations9/161
SepsisInfections and infestations5/161
Aspartate aminotransferase increasedInvestigations4/161
Acute kidney injuryRenal and urinary disorders4/161
Pleural effusionRespiratory, thoracic and mediastinal disorders4/161
Gastrointestinal haemorrhageGastrointestinal disorders3/161
Alanine aminotransferase increasedInvestigations3/161
DehydrationMetabolism and nutrition disorders3/161
HyponatraemiaMetabolism and nutrition disorders3/161
Mental status changesPsychiatric disorders3/161
Most frequent other events
Showing 10 of 457
Most frequent other events
EventAcalabrutinib + Pembrolizumab
DiarrhoeaGastrointestinal disorders73/161
FatigueGeneral disorders57/161
HeadacheNervous system disorders57/161
CoughRespiratory, thoracic and mediastinal disorders44/161
NauseaGastrointestinal disorders43/161
Decreased appetiteMetabolism and nutrition disorders42/161
AnaemiaBlood and lymphatic system disorders35/161
VomitingGastrointestinal disorders33/161
DizzinessNervous system disorders32/161
DyspnoeaRespiratory, thoracic and mediastinal disorders29/161

Baseline characteristics

All participants in this study received both study drugs and were therefore analyzed together as a single treatment arm. Participants receiving the different regimens were not analyzed separately by regimen, as the study was designed to assess the safety of the combination study treatment.

Age, Continuous
Age, Continuous(Years)Acalabrutinib + Pembrolizumab
Mean62.4 ± 14.6
Sex: Female, Male
Sex: Female, Male(Participants)Acalabrutinib + Pembrolizumab
Female63
Male98
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acalabrutinib + Pembrolizumab
Hispanic or Latino11
Not Hispanic or Latino148
Not Reported2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acalabrutinib + Pembrolizumab
American Indian or Alaska Native0
Asian4
Black or African American5
Native Hawaiian or Other Pacific Islander2
White141
Not Reported9
Region of Enrollment
Region of Enrollment(Participants)Acalabrutinib + Pembrolizumab
USA161
08

Study locations

19 sites
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Denver, Colorado 80218, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Niles, Illinois 60714, United States
  • Research Site
    Boston, Massachusetts 2215, United States
  • Research Site
    Rochester, Minnesota 55905-0001, United States
  • Research Site
    Omaha, Nebraska 68198-7680, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78217, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Roanoke, Virginia 24014, United States
  • Research Site
    Vancouver, Washington 98684, United States
  • Research Site
    Yakima, Washington 98902, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Jul 2020, 64 months.

Results were first posted in May 2022, 1 year 9 months after primary completion.

Of 43 industry-sponsored phase 1/2 interventional studies under Lymphoma, Follicular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 103. This study's 64 months is close to that.

Counting every sponsor, half of 88 studies reached it within 73 months; a quarter within 50 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2015
First posted
Feb 12, 2015
StartActual
Feb 20, 2015
Primary completionActual
Jul 14, 2020
CompletionActual
Oct 27, 2025
Results first posted
May 6, 2022
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02362035
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Feb 12, 2015
Start date
Feb 20, 2015
Primary completion
Jul 14, 2020
Completion
Oct 27, 2025
Results posted
May 6, 2022
Last update
May 13, 2026

Study contacts

AstraZeneca Clinical Study Information Center
study director · 1-877-240-9479 - information.center@astrazeneca.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion